Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

NCT04572165 · clinicaltrials.gov ↗

UNKNOWN

Status

600000

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Ozempic®
DRUG: Active Comparator
DRUG: Rybelsus®

Sponsor

Novo Nordisk A/S

Collaborators

[object Object]